Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01041404
Registration number
NCT01041404
Ethics application status
Date submitted
29/12/2009
Date registered
31/12/2009
Date last updated
5/11/2014
Titles & IDs
Public title
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
Query!
Scientific title
A Randomized, Open-label Study of the Effect of First-line Herceptin in Combination With a Fluoropyrimidine and Cisplatin Versus Chemotherapy Alone on Overall Survival in Patients With HER2-positive Advanced Gastric Cancer
Query!
Secondary ID [1]
0
0
BO18255
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Gastric Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Stomach
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Trastuzumab
Treatment: Drugs - Fluorouracil
Treatment: Drugs - Cisplatin
Treatment: Drugs - Capecitabine
Experimental: Trastuzumab, Fluoropyrimidine, Cisplatin - Participants received an initial loading dose of 8 milligrams per kilogram (mg/kg) trastuzumab i.v. on Day 1 of cycle, followed by 6 mg/kg i.v. every 3 weeks until disease progression; 800 mg/m2 fluorouracil i.v. on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
Active comparator: Fluoropyrimidine, Cisplatin - Participants received 800 milligrams per square meter (mg/m2) fluorouracil intravenous (i.v.) on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine orally (p.o.) twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
Treatment: Drugs: Trastuzumab
Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression
Treatment: Drugs: Fluorouracil
800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
Treatment: Drugs: Cisplatin
80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles
Treatment: Drugs: Capecitabine
1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS) - Percentage of Participants With an Event
Query!
Assessment method [1]
0
0
OS was defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up.
Query!
Timepoint [1]
0
0
Baseline (BL), Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
Query!
Primary outcome [2]
0
0
Overall Survival - Time to Event
Query!
Assessment method [2]
0
0
The median time, in months, from the date of randomization to the date of an OS event. Participants were censored at the last date tumor measurement, the last date in the study drug log, or the date of last follow-up.
Query!
Timepoint [2]
0
0
BL, Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
Query!
Secondary outcome [1]
0
0
Progression-Free Survival (PFS) - Percentage of Participants With an Event
Query!
Assessment method [1]
0
0
PFS was defined as the time from the date of randomization to the date of the first documentation of progressive disease (PD) or date of death, whichever occurs first. For target lesions (TL), PD was defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD) of TLs, taking as a reference the smallest SLD recorded since the treatment started, or the appearance of one or more lesions. For non-target lesions (NTL), PD was defined as an unequivocal progression of existing NTLs. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up.
Query!
Timepoint [1]
0
0
BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
Query!
Secondary outcome [2]
0
0
Progression-Free Survival - Time to Event
Query!
Assessment method [2]
0
0
The median time, in months, from the date of randomization to the date of a PFS event. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up.
Query!
Timepoint [2]
0
0
BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
Query!
Secondary outcome [3]
0
0
Time to Progression (TTP) - Percentage of Participants With an Event
Query!
Assessment method [3]
0
0
TTP was defined as the time from the date of randomization and the date of the first occurrence of PD. Participants were censored at the last date of tumor assessment, the last date in the study drug log, or the last date of follow-up.
Query!
Timepoint [3]
0
0
BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
Query!
Secondary outcome [4]
0
0
Time to Progression - Time to Event
Query!
Assessment method [4]
0
0
The median time, in months, from the date of randomized to the date of a TTP event. Participants were censored at the last date of tumor assessment, the last date in the study drug log, or the last date of follow-up.
Query!
Timepoint [4]
0
0
BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Determined by Response Evaluation Criteria in Solid Tumors (RECIST)
Query!
Assessment method [5]
0
0
For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD. For NTLs, a CR was defined as the disappearance of all NTLs and normalization of tumor marker levels.
Query!
Timepoint [5]
0
0
BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
Query!
Secondary outcome [6]
0
0
Duration of Response - Percentage of Participants With an Event
Query!
Assessment method [6]
0
0
Duration of response was defined for responders as the time from the date on which the CR or PR was first recorded to the date on which PD is first noted. Participants were censored on the date of death, the date of last tumor measurement, the last date in study drug log, or the date of last follow-up.
Query!
Timepoint [6]
0
0
BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
Query!
Secondary outcome [7]
0
0
Duration of Response
Query!
Assessment method [7]
0
0
The median time, in months, of the duration of response. Participants were censored at the date of death, the date of last tumor measurement, the last date in study drug log, or the date of last follow-up.
Query!
Timepoint [7]
0
0
BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
Query!
Secondary outcome [8]
0
0
Percentage of Participants With Clinical Benefit
Query!
Assessment method [8]
0
0
Clinical benefit was defined as stable disease (SD), CR, or PR for 6 weeks or longer as determined by RECIST. For TLs, SD was defined as neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD, taking as a reference the smallest SLD recorded since treatment had started. For NTLs, SD was defined as a persistence of one or more NTLs and/or maintenance of tumor marker levels above the normal limits.
Query!
Timepoint [8]
0
0
BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
Query!
Secondary outcome [9]
0
0
European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores
Query!
Assessment method [9]
0
0
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score equals (=) better level of functioning or greater degree of symptoms.
Query!
Timepoint [9]
0
0
BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
Query!
Secondary outcome [10]
0
0
EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores
Query!
Assessment method [10]
0
0
The QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms.
Query!
Timepoint [10]
0
0
BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
Query!
Secondary outcome [11]
0
0
Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)
Query!
Assessment method [11]
0
0
The participant assessed their pain on a 0 to 100 millimeter (mm) horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". A negative change indicated improvement.
Query!
Timepoint [11]
0
0
BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
Query!
Secondary outcome [12]
0
0
Percentage of Participants With a Change in Analgesic Medication During the Study
Query!
Assessment method [12]
0
0
Analgesic medications were recorded throughout the study until disease progression.
Query!
Timepoint [12]
0
0
BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
Query!
Secondary outcome [13]
0
0
Body Weight (Kilograms [kg]) at BL
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
BL
Query!
Secondary outcome [14]
0
0
Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight
Query!
Assessment method [14]
0
0
Change in body weight was categorized as an increase of greater than (\>)5 percent (%), no change (plus or minus \[±\]5%), decrease of \>5-10%, or a decrease of \>10% from BL to the end of study. Time windows were applied in order to assign visits to weight measurements, and the lowest post-screening value recorded was used for the analysis. The percentage change in weight from screening was summarized over time.
Query!
Timepoint [14]
0
0
BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis
Query!
Secondary outcome [15]
0
0
Steady State Trastuzumab Area Under the Concentration (AUC)
Query!
Assessment method [15]
0
0
Individual steady state predicted exposure, as assessed by median AUC (measured as mg multiplied by \[\*\] day per liter \[L\]) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion. Individual steady state AUC was calculated using all available PK samples from all timepoints.
Query!
Timepoint [15]
0
0
Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106
Query!
Secondary outcome [16]
0
0
Trastuzumab Minimum Serum Concentration (Cmin)
Query!
Assessment method [16]
0
0
Median Cmin (measured as milligrams per liter \[mg/L\]) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion.
Query!
Timepoint [16]
0
0
Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106
Query!
Secondary outcome [17]
0
0
Trastuzumab Maximum Serum Concentration (Cmax)
Query!
Assessment method [17]
0
0
Median Cmax (measured as mg/L) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion.
Query!
Timepoint [17]
0
0
Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106
Query!
Eligibility
Key inclusion criteria
* Adult patients >=18 years of age
* Inoperable locally advanced, recurrent, and/or metastatic cancer of the stomach or gastro-esophageal junction
* Adenocarcinoma
* HER2-positive tumors
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Previous chemotherapy for advanced/metastatic disease
* Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome
* History of cardiac disease
* Dyspnoea at rest, due to complications of advanced malignancy or other disease, or patients who require supportive oxygen therapy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/06/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
584
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Kurralta Park
Query!
Recruitment hospital [3]
0
0
- Melbourne
Query!
Recruitment hospital [4]
0
0
- Milton
Query!
Recruitment hospital [5]
0
0
- Perth
Query!
Recruitment hospital [6]
0
0
- Sydney
Query!
Recruitment postcode(s) [1]
0
0
5011 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
5037 - Kurralta Park
Query!
Recruitment postcode(s) [3]
0
0
3128 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
4064 - Milton
Query!
Recruitment postcode(s) [5]
0
0
6008 - Perth
Query!
Recruitment postcode(s) [6]
0
0
2217 - Sydney
Query!
Recruitment outside Australia
Country [1]
0
0
Belgium
Query!
State/province [1]
0
0
Leuven
Query!
Country [2]
0
0
Brazil
Query!
State/province [2]
0
0
Barretos
Query!
Country [3]
0
0
Brazil
Query!
State/province [3]
0
0
Rio de Janeiro
Query!
Country [4]
0
0
Brazil
Query!
State/province [4]
0
0
Sao Paulo
Query!
Country [5]
0
0
China
Query!
State/province [5]
0
0
Beijing
Query!
Country [6]
0
0
China
Query!
State/province [6]
0
0
Guangdong
Query!
Country [7]
0
0
China
Query!
State/province [7]
0
0
Guangzhou
Query!
Country [8]
0
0
China
Query!
State/province [8]
0
0
Jiangsu
Query!
Country [9]
0
0
China
Query!
State/province [9]
0
0
Nanjing
Query!
Country [10]
0
0
China
Query!
State/province [10]
0
0
Shanghai
Query!
Country [11]
0
0
China
Query!
State/province [11]
0
0
Suzhou
Query!
Country [12]
0
0
China
Query!
State/province [12]
0
0
Wuhan
Query!
Country [13]
0
0
Costa Rica
Query!
State/province [13]
0
0
San Jose
Query!
Country [14]
0
0
Costa Rica
Query!
State/province [14]
0
0
San José
Query!
Country [15]
0
0
Denmark
Query!
State/province [15]
0
0
Herlev
Query!
Country [16]
0
0
Denmark
Query!
State/province [16]
0
0
Odense
Query!
Country [17]
0
0
Finland
Query!
State/province [17]
0
0
Tampere
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Brest
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Caen
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Colmar
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Lille
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Marseille
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Reims
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Rouen
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Strasbourg
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Heidelberg
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Mainz
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
München
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Trier
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Witten
Query!
Country [31]
0
0
Guatemala
Query!
State/province [31]
0
0
Guatemala City
Query!
Country [32]
0
0
India
Query!
State/province [32]
0
0
Hyderabad
Query!
Country [33]
0
0
India
Query!
State/province [33]
0
0
Kochi
Query!
Country [34]
0
0
India
Query!
State/province [34]
0
0
Mumbai
Query!
Country [35]
0
0
India
Query!
State/province [35]
0
0
New Delhi
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Ancona
Query!
Country [37]
0
0
Italy
Query!
State/province [37]
0
0
Firenze
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Napoli
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Parma
Query!
Country [40]
0
0
Italy
Query!
State/province [40]
0
0
Roma
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Udine
Query!
Country [42]
0
0
Japan
Query!
State/province [42]
0
0
Aichi
Query!
Country [43]
0
0
Japan
Query!
State/province [43]
0
0
Chiba
Query!
Country [44]
0
0
Japan
Query!
State/province [44]
0
0
Ehime
Query!
Country [45]
0
0
Japan
Query!
State/province [45]
0
0
Fukuoka
Query!
Country [46]
0
0
Japan
Query!
State/province [46]
0
0
Hyogo
Query!
Country [47]
0
0
Japan
Query!
State/province [47]
0
0
Nagano
Query!
Country [48]
0
0
Japan
Query!
State/province [48]
0
0
Osaka
Query!
Country [49]
0
0
Japan
Query!
State/province [49]
0
0
Saitama
Query!
Country [50]
0
0
Japan
Query!
State/province [50]
0
0
Shizuoka
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Tochigi
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Tokyo
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Yamagata
Query!
Country [54]
0
0
Korea, Republic of
Query!
State/province [54]
0
0
Buchun
Query!
Country [55]
0
0
Korea, Republic of
Query!
State/province [55]
0
0
Bundang City
Query!
Country [56]
0
0
Korea, Republic of
Query!
State/province [56]
0
0
Daegu
Query!
Country [57]
0
0
Korea, Republic of
Query!
State/province [57]
0
0
Goyang-si
Query!
Country [58]
0
0
Korea, Republic of
Query!
State/province [58]
0
0
Pusan
Query!
Country [59]
0
0
Korea, Republic of
Query!
State/province [59]
0
0
Seoul
Query!
Country [60]
0
0
Mexico
Query!
State/province [60]
0
0
Guadalajara
Query!
Country [61]
0
0
Mexico
Query!
State/province [61]
0
0
Merida
Query!
Country [62]
0
0
Mexico
Query!
State/province [62]
0
0
Mexico City
Query!
Country [63]
0
0
Mexico
Query!
State/province [63]
0
0
Monterrey
Query!
Country [64]
0
0
Panama
Query!
State/province [64]
0
0
Panama City
Query!
Country [65]
0
0
Peru
Query!
State/province [65]
0
0
Callao
Query!
Country [66]
0
0
Peru
Query!
State/province [66]
0
0
Lima
Query!
Country [67]
0
0
Portugal
Query!
State/province [67]
0
0
Braga
Query!
Country [68]
0
0
Portugal
Query!
State/province [68]
0
0
Coimbra
Query!
Country [69]
0
0
Portugal
Query!
State/province [69]
0
0
Faro
Query!
Country [70]
0
0
Portugal
Query!
State/province [70]
0
0
Guimaraes
Query!
Country [71]
0
0
Portugal
Query!
State/province [71]
0
0
Lisboa
Query!
Country [72]
0
0
Portugal
Query!
State/province [72]
0
0
Porto
Query!
Country [73]
0
0
Russian Federation
Query!
State/province [73]
0
0
Chelyabinsk
Query!
Country [74]
0
0
Russian Federation
Query!
State/province [74]
0
0
Ekaterinburg
Query!
Country [75]
0
0
Russian Federation
Query!
State/province [75]
0
0
Ivanovo
Query!
Country [76]
0
0
Russian Federation
Query!
State/province [76]
0
0
Kazan
Query!
Country [77]
0
0
Russian Federation
Query!
State/province [77]
0
0
Moscow
Query!
Country [78]
0
0
Russian Federation
Query!
State/province [78]
0
0
Ryazan
Query!
Country [79]
0
0
Russian Federation
Query!
State/province [79]
0
0
Samara
Query!
Country [80]
0
0
Russian Federation
Query!
State/province [80]
0
0
St Petersburg
Query!
Country [81]
0
0
Russian Federation
Query!
State/province [81]
0
0
UFA
Query!
Country [82]
0
0
Russian Federation
Query!
State/province [82]
0
0
Yaroslavl
Query!
Country [83]
0
0
South Africa
Query!
State/province [83]
0
0
Cape Town
Query!
Country [84]
0
0
South Africa
Query!
State/province [84]
0
0
Durban
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Barcelona
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Girona
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Madrid
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Valencia
Query!
Country [89]
0
0
Taiwan
Query!
State/province [89]
0
0
Changhua
Query!
Country [90]
0
0
Taiwan
Query!
State/province [90]
0
0
Kaohsiung
Query!
Country [91]
0
0
Taiwan
Query!
State/province [91]
0
0
Taipei
Query!
Country [92]
0
0
Turkey
Query!
State/province [92]
0
0
Istanbul
Query!
Country [93]
0
0
Turkey
Query!
State/province [93]
0
0
Izmir
Query!
Country [94]
0
0
Turkey
Query!
State/province [94]
0
0
Shhiye, Ankara
Query!
Country [95]
0
0
United Kingdom
Query!
State/province [95]
0
0
Birmingham
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
Denbigh
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
Dundee
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Glasgow
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Manchester
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Weston Super Mare
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Wirral
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Wolverhampton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Chugai Pharmaceutical
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This parallel, randomized, open-label, multi-centre study will evaluate the effect on overall survival of trastuzumab (Herceptin) in combination with a chemotherapy compared to the chemotherapy alone in patients with HER2-positive advanced gastric cancer. Trastuzumab (Herceptin) will be administered as intravenous infusion of 6 mg/kg (loading dose 8 mg/kg) every 3 weeks. The chemotherapy consists of a combination of 6 cycles of fluorouracil (800 mg/m2/day intravenous infusion every 3 weeks) and cisplatin (80 mg/m2 intravenous infusion every 3 weeks), or capecitabine (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks) and cisplatin (80 mg/m2 intravenous infusion every 3 weeks). Treatment with trastuzumab (Herceptin) will continue until disease progression. The target sample size is 300-600 patients.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01041404
Query!
Trial related presentations / publications
Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, Lopez-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Ruschoff J. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015 Jul;18(3):476-84. doi: 10.1007/s10120-014-0402-y. Epub 2014 Jul 20. Satoh T, Bang YJ, Gotovkin EA, Hamamoto Y, Kang YK, Moiseyenko VM, Ohtsu A, Van Cutsem E, Al-Sakaff N, Urspruch A, Hill J, Weber HA, Chung HC; ToGA Trial Investigators. Quality of life in the trastuzumab for gastric cancer trial. Oncologist. 2014 Jul;19(7):712-9. doi: 10.1634/theoncologist.2014-0058. Epub 2014 Jun 20. Satoh T, Omuro Y, Sasaki Y, Hamamoto Y, Boku N, Tamura T, Ohtsu A. Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer. Cancer Chemother Pharmacol. 2012 Apr;69(4):949-55. doi: 10.1007/s00280-011-1783-9. Epub 2011 Nov 25. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Erratum In: Lancet. 2010 Oct 16;376(9749):1302.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01041404
Download to PDF